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Abstract: 
Background and Aim: Dentin hypersensitivity (DH) is a common and harrowing dental 
condition. A Novel Biomin-F technology that contains 5% Fluorocalcium phosphosilicate 
bioactive glass has been introduced. It forms Fluorapatite which is more stable towards acid 
erosion. There is a lack of literature with the utility of this toothpaste in treating DH. 
Therefore, the authors of this randomized clinical trial have aimed to compare and evaluate 
the efficacy of 5% Fluorocalcium Phosphosilicate with an 8% Arginine and Calcium 
carbonate and Placebo toothpaste. 
Methods: A total of 75 patients clinically diagnosed with DH were randomly divided into 
Group A: 5% Fluorocalcium Phosphosilicate, Group B: 8% Arginine and Calcium carbonate, 
and Group C: Placebo. The DH was evaluated by tactile and evaporative stimuli and a visual 
analog scale (VAS) was used for evaporative stimuli at Pre-baseline, Baseline (15 days) and 
Post-baseline (1 month). 
Results: The results showed symptoms of DH were reduced in all three groups. However, 
Group A showed a better reduction of DH than the other two groups. 
Conclusion: The toothpaste containing 5% Fluoro Calcium Phosphosilicate was reported to 
be more efficacious than the other two toothpastes in managing DH. 
Practical Implications: This  novel  development  opens  up  a  unique  opportunity  in  the 
prevention and management of DH and may also be beneficial in preventing acid erosion of 
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the tooth surface and in the maintenance of oral  hygiene by reducing the effects of plaque 
accumulation and gingival inflammation. 
Keywords: Dentin sensitivity, Calcium carbonate, Fluorapatite, Arginine, Toothpastes, 
Visual analog scale, Apatites. 
Introduction: 
Dentin Hypersensitivity (DH) is an enigma which is frequently encountered but is not fully 
understood.
1
 It is exemplified by a short, sharp pain arising from exposed dentin in response 
to a stimuli; typically thermal, evaporative, tactile, osmotic or chemical and which cannot be 
ascribed to any other form of dental defect or pathology.
2
 Based on the procurable 
disquisition the distribution data primarily neglects the number of teeth affected and the range 
of pain scores experienced per individual. This absence of information makes it difficult to 
make an accurate judgement of how DH impacts on the quality of life of 
sufferers.
1
Essentially the treatment of DH can be either by the interruption of pulp nerve 
response or through tubule occlusion. Tubule occlusion has been demonstrated to occur by 
clinical observation and through in vitro and in situ studies. Unfortunately, the resistance of 
the deposited material to etiological agents, notably abrasion and/or erosion, is rarely tested, 
and certainly some deposits on the exposed dentin surface are very acid labile.
1,3 
 Currently 
the epitome in the tubular occlusion approach for the treatment of DH includes formulations 
such as Novamin® and Pro-Argin®. The Novamin formulation formed a hydroxycarbonate 
like apatite (HCA) on the dentin surface and occluded the tubules.
4
 However, an in vitro 
study
5
 comparing HCA to Fluorapatite (FAP) crystals in a tris buffer solution for acid erosion 
and reported that FAP was more acid resistant. Based on the results of this study, the Biomin-
F formulation was conceptualized which contains 5% Fluorocalcium phosphosilicate as its 
active ingredient that subsequently forms FAP crystals in contact with saliva rapidly 
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occluding the tubules.  This recently introduced formulation has not been extensively 
researched by clinicians and researchers. Currently there appears to be limited in vivo studies
6
 
on Biomin-F, although several in vitro studies
7,8
 have published.
 
Therefore as a result of the 
limited data available that would support the efficacy of this formulation it was considered 
appropriate to conduct a study to evaluate the efficacy of Biomin-F for the treatment of DH.  
There are numerous products that have been demonstrated to be effective for the treatment of 
DH, for example, Pro-Argin® desensitizing toothpastes based on its tubular occluding 
properties.
9-13 
It was therefore considered appropriate to compare Biomin-F® to the Pro-
Argin® formulation in the management of DH.  The primary objective was to evaluate the 
reduction of DH whereas the secondary objective was to evaluate changes with PI and GI. 
The null hypothesis of the study was that there was no statistically significant difference in 
the efficacy of the Biomin-F® and Pro-Argin® toothpastes, whereas the alternate hypothesis 
was that Biomin-F® toothpaste was more efficacious than Pro-Argin® comparator in 
managing DH. 
Materials and methods:  
Study design: 
The study was a randomized, triple blinded, two treatment, parallel arm clinical trial with an 
allocation ratio of 1:1. The study protocol was approved by the Institutional Review Board at 
the SDM College of Dental Sciences and Hospital, Rajiv Gandhi University of Health 
Sciences (IRB.No. 2016/P/PERIO/64) and was registered with the Clinical trials registry of 
India (CTRI/2018/05/014136). Each subject provided informed consent after a thorough 
explanation of the nature, risks, and benefits of the clinical investigation.  
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Study Population: 
Patients reporting to the Department of Periodontology and Oral Implantology were screened 
clinically for the presence of DH and were included in the study based on the inclusion and 
exclusion criteria. The inclusion criteria of the study were: Subjects with a gingival index 
score of  ≤2; Subjects who were medically/systemically fit and had no dental problems/active 
periodontitis apart from experiencing DH; Subjects with cervical abrasion, abfraction or 
gingival recession; Subjects of both genders of age 18-70 years; Non-lactating females; Non-
smokers; Subjects who agreed to be compliant during the study. The exclusion criteria were: 
Subjects using any existing desensitizing therapy; Subjects with attrition; Medical (including 
psychiatric) and pharmacotherapeutic histories that may compromise the protocol and 
assessment of DH; Allergies and idiosyncratic responses to any of the product ingredients; 
Periodontal surgery in the preceding 3 months; Orthodontic appliance treatment within the 
previous 3 months; Teeth or supporting structures with any other painful pathology or 
defects; Teeth restored in the preceding 3 months and those with restorations extending into 
the test area; Abutment teeth for fixed or removable prostheses. 
Sample Size:  
The sample size estimation was undertaken using the G- power software. The effect size was 
1.01, while the alpha error (%) was 5% and the power (%) was 95%. Hence the sample size 
calculated was 25 in each group. 
Randomization: 
The toothpastes concealed in plain white tubes were allocated randomly by a third person 
who was not involved in the study. The list of subjects and the group to which they belong 
was known only to the third person who kept a record within a computer data sheet. The 
allocation concealment was completed using case numbers assigned to each subject. The 
single, blinded, calibrated investigator performed all the clinical examination to avoid any 
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bias. The statistician was also blinded and was not aware of the allocation of the toothpastes 
to the individuals with the three groups.  
Study Protocol: 
The study was conducted on 75 subjects. The participants were categorized into following 
three groups:  
Group-A: 25 subjects who were given a test toothpaste (5% Fluorocalcium 
phosphosilicate/Biomin-F®). 
Group-B: 25 subjects who were given a comparative toothpaste (8% Arginine and calcium 
carbonate/ Pro-Argin®). 
Group-C: 25 subjects who were given a placebo toothpaste. 
The following clinical parameters were recorded at pre-baseline (day 1): 
• Gingival Index (Loe and Sillness -1963) 
• Plaque Index (Sillness and Loe-1964) 
• Visual analog score (VAS) for evaluating DH using an air blast stimuli.  
The Gingival Index and Plaque Index were assessed in the teeth having dentinal 
hypersensitivity. DH was also assessed by tactile examination by running a sharp explorer 
over the exposed buccal/ cervical region. An evaporative stimulus was applied using a 3 s 
blast of air from a dental unit syringe at 40–65 psi directed perpendicular and at a distance of 
1–3mm to the exposed buccal cervical region. A VAS was scored only for the air blast 
stimuli using a scale from 0= no pain to 10=extreme pain. Subjects with a VAS score ≥ 5 
were included in the study. Scaling and root planing was performed on each subject as well 
as oral hygiene instruction(s) with the demonstration of the modified bass technique of 
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toothbrushing was shown to each subject. At baseline 15 days after the pre-baseline all 
subjects were recalled for evaluation where all the parameters were reassessed. Following 
this evaluation the subjects were provided with a soft bristle toothbrush and the toothpastes 
were randomly allocated by a third person who was not a part of the study. After this 
appointment subjects were recalled after a 1 month interval at the post-baseline where all the 
parameters were reassessed. In this study, our primary outcome to be evaluated was reduction 
of DH whereas the secondary outcome was to evaluate changes with PI and GI. 
Statistical Analysis: 
The comparison of the three study groups with respect to the pre-baseline, baseline and post-
baseline for PI, GI, and VAS scores was performed by Kruskal Wallis ANOVA, whereas pair 
wise comparisons were undertaken by Mann-Whitney U test. The percentage changes were 
evaluated by the Wilcoxon matched pairs test. The p value was kept as < 0.05. 
Results: 
The PI scores were found to be significant for Group A as compared to Group C. While a 
better reduction was found for Group A as compared to Group B and Group B as compared 
to Group C, but the differences were not statistically significant (Table-1/Figure-1). The GI 
scores were found to be significant for Group A as compared to Group C. Similar to the PI 
scores, the GI scores as well showed a better reduction for Group A as compared to Group B 
and Group B as compared to Group C, but the differences were not statistically significant 
(Table-2/Figure-2). The VAS scores were found to be significant for Group A as compared to 
Group B and Group C and for Group B as compared to Group C (Table-3/Figure-3).  
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Discussion: 
In this study, Group-B was provided with a comparator Pro-Argin®formulation because 
several published studies
9-13 
evaluating Pro-Argin®  formulations comparing it with other 
available tubule occluding agents reported that Pro-Argin® toothpastes were superior to the 
other toothpastes. In this study, Group-A showed a better clinical reduction in DH than 
Group-B and Group-C and this difference was found to be statistically significant. The 
Group-B, however, also showed significant reduction of DH on an intragroup comparison 
and on comparision with Group-C.  
An invivo study
6
 comparing the 5% Fluorocalcium phosphosilicate toothpaste with 5% 
potassium nitrate, 10% strontium chloride, and a herbal formulation and reported that the 5% 
Fluorocalcium phosphosilicate toothpaste was more effective than the other toothpastes.
6
 The 
authors indicated that the Biomin-F toothpaste contained a smaller particle size which 
reduced their abrasiveness and increased their penetration into the dentinal tubules and also 
reported that these particles could chemically bind to the tooth surface due to the presence of 
specific polymers which increased their retentiveness within the tubules.
6
 An in vitro study
4 
 
reported that the components within the 5% Fluorocalcium phosphosilicate dentifrice slowly 
dissolved to release calcium, phosphate and fluoride ions from a single composition which 
increased their bioavailability. These ions precipitate and crystallize to form FAP over the 
dentin surface and within the dentinal tubules that provide a deep occlusion within the 
tubules.
4
 Also the fluoride was present within the glass instead of as a soluble additive hence 
more FAP formation was obtained and  no undesirable fluorite was formed.
4 
 Another in vitro 
study
5
 reported that FAP has a fluoride ion (F
-
) which fits in the center of the triangle formed 
by the calcium  ion (Ca
+2
) in the apatite lattice. This stoichiometry provides the structure with 
more stability and a higher bond strength hence making it more acid resistant. The HCA 
crystal has the hydroxyl ion that is displaced above the Ca+2 triangle which distorts the 
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crystals and decreases the bond strength making it less resistant to an acid challenge.
5
 Also 
one more in vitro study
14
 demonstrated that the higher phosphate content helped in the rapid 
degradation of the glass lattice and increased the pH causing a rapid precipitation of ions 
forming FAP at a higher rate and occluding the dentinal tubules. The FAP formed rapidly and 
tubule occlusion was obtained as early as 6 hrs in comparison to the other toothpastes with 
soluble fluorides which took 7 days to occlude dentinal tubules.
14
 These reasons may explain 
the superior efficacy of a 5% Fluorocalcium phosphosilicate toothpaste demonstrated in this 
randomized clinical trial. 
Group-B were allocated the Pro-Argin® formulation containing toothpaste. A study 
comparing a Pro-Argin®  formulation to a toothpaste containing 2% potassium ion and 
reported that the Pro-Argin®  formulation was more effective.
11
 Another study comparing a 
Pro-Argin®  formulation with an 8% strontium acetate toothpaste and reported that the Pro-
Argin®  toothpaste to be more effective.
12
 An invivo study
9
 compared a Pro-Argin®  
formulation with a Novamin® formulation and Hydroxyapatite nanoparticles and observed 
that the Pro-Argin was superior to the Novamin® formulation but not to the hydroxyapatite 
nanoparticle formulation.
9
 The Arginine (positively charged) and calcium carbonate from the 
desensitizing paste containing the Pro-Argin formulation in contact with the saliva binds to 
the negatively charged dentin to deposit Arginine calcium bicarbonate which is a dentin like 
mineral. This layer occludes the tubules up to 2 microns and has been reported to provide 
relief from DH.
3,13
 Other reported studies
10,13
 on acid erosion of the mineral layer formed by 
Pro-Argin® formulations have indicated that the layer was resistant to normal pulpal 
pressures and partially to an acid challenge. Therefore as evidenced in the present study the 
Pro-Argin® formulation showed a significant reduction of DH from prebaseline to 
postbaseline compared with Group-C.  
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The secondary objective of this study was to assess the effects of Biomin-F® on GI and PI. 
An in vitro study,
15
 where it was observed that a F
-
 containing Bioactive Glass (BAG’s) had 
an antimicrobial effects on several periodontal pathogens.
15
 Therefore in the present study we 
evaluated the effects of the test and control toothpastes on both GI and PI. Our results showed 
that only Group-A (Biomin-F) showed a significant reduction of GI and PI at post-
baseline.One plausible mechanism that  may explain this finding would be that the F
-
 ion in 
the BAG initiates disruption in some of the periodontal pathogens. Furthermore, the pH 
elevation caused by the BAG sodium release is generally unfavourable for most bacteria and 
the increased osmotic pressure from ion dissolution, creates an environment where the 
bacteria cannot grow.
15
 This causes a reduction in the bacterial load and its accumulation and 
may therefore be the reason that there was an observed clinical reduction in the PI scores. 
The reduction in the bacterial load and accumulation may also cause a reduction in 
inflammation thereby decreasing the GI scores and as such may explain why Group-A in 
particular showed a significant reduction of both the PI and GI scores at the postbaseline 
timepoint.  
This study, however, is not without limitations. The main limitation of this study was that the 
long term efficacy of the test toothpaste was not evaluated. Furthermore, the results of this 
study cannot be generalized as non random sampling was undertaken. Although the results 
from the present study would indicate some short term benefit from using a Biomin-F ® 
toothpaste it would be appropriate to conduct further long term randomized clinical trials (≥ 6 
weeks) to determine whether this novel toothpaste may be an effective tubular occluding 
agent for the treatment of DH.  
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Conclusion: 
In conclusion, all three groups showed a reduction in DH, however, only  Group-A (5% 
Fluorocalcium phosphosilicate) showed a maximal reduction in DH and appeared within the 
limitations of the study to be more efficacious than both the comparator and placebo 
toothpastes in managing DH. Also the 5% Fluorocalcium phosphosilicate toothpaste showed 
a reduction  in both the PI and GI scores as compared to the other two groups at postbaseline 
which may be as a result of its anti-bacterial and anti-inflammatory activity. Further clincal 
trials, however, are warranted in this direction to evaluate the efficacy of this novel toothpaste 
against other established comparator toothpastes. 
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Table-1: Comparison of the three study groups (A, B, C) with respect to pre-baseline, 
baseline and post-baseline PI scores by Kruskal Wallis ANOVA 
Groups Pre-baseline Baseline Post-baseline 
Mean SD Mean SD Mean SD 
Group A 1.52 0.25 1.54 0.26 0.59 0.21 
Group B 1.53 0.28 1.55 0.27 0.62 0.22 
Group C 1.51 0.33 1.54 0.33 0.72 0.30 
H-value 0.1200 0.1290 3.6280 
p-value 0.9420 0.9370 0.1630 
Pair wise comparisons by Mann-Whitney U test 
Group A vs Group B p=0.9227 p=0.9227 p=0.6071 
Group A vs Group C p=0.7710 p=0.7785 p=0.0407* 
Group B vs Group C p=0.7415 p=0.6766 p=0.1094 
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Table-2: Comparison of the three study groups (A, B, C) with respect to pre-baseline, 
baseline and post-baseline GI scores by Kruskal Wallis ANOVA 
Groups Pre-baseline Baseline Post-baseline 
Mean SD Mean SD Mean SD 
Group A 1.76 0.27 1.77 0.26 0.63 0.19 
Group B 1.66 0.31 1.67 0.31 0.69 0.27 
Group C 1.64 0.36 1.65 0.36 0.75 0.16 
H-value 1.5980 1.6860 6.1360 
p-value 0.4500 0.4300 0.0470* 
Pair wise comparisons by Mann-Whitney U test 
Group A vs Group B p=0.2483 p=0.2366 p=0.3320 
Group A vs Group C p=0.3773 p=0.3879 p=0.0110* 
Group B vs Group C p=0.9768 p=0.9613 p=0.4151 
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Table-3: Comparison of the three study groups (A, B, C) with respect to pre-baseline, 
baseline and post-baseline VAS scores by Kruskal Wallis ANOVA 
Groups Pre-baseline Baseline Post-baseline 
Mean SD Mean SD Mean SD 
Group A 5.58 0.65 5.58 0.65 0.51 0.46 
Group B 5.42 1.04 5.42 1.04 2.36 0.97 
Group C 5.25 0.70 5.25 0.70 4.02 0.83 
H-value 5.1280 5.1280 56.0480 
p-value 0.0770 0.0770 0.0001* 
Pair wise comparisons by Mann-Whitney U test 
Group A vs Group B p=0.0842 p=0.0842 p=0.0001* 
Group A vs Group C p=0.0489* p=0.0489* p=0.0001* 
Group B vs Group C p=0.6766 p=0.6766 p=0.0001* 
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Figure Legends: 
Figure-1: Comparison of three study groups (A, B, C) with respect to pre-baseline, baseline 
and post-baseline Plaque Index scores  
Figure-2: Comparison of three study groups (A, B, C) with respect to pre-baseline, baseline 
and post-baseline Gingival Index scores  
Figure-3: Comparison of three study groups (A, B, C) with respect to pre-baseline, baseline 
and post-baseline Visual Analog Scale scores  
 
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
